A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Kurteya nûçeyê
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Nûçeyên dawî yên weşangerên pêbawer bi kurtasî bişopîne. Ji bo hûrguliyan lînka çavkaniya orîjînal veke.